Drug Patent Watch

APRIL 24, 2024

Annual Drug Patent Expirations for AYVAKIT Ayvakit is a drug marketed by Blueprint Medicines and is included in one NDA. It is available from one supplier. There are four patents… Source

Medicine 59

Medicine Drugs Marketing 59

Fierce Pharma

DECEMBER 12, 2023

Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S. Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages.

Medicine 141

Medicine Generic Drugs Drugs Doctors 141

Bio Pharma Dive

MARCH 11, 2024

Roche said its experimental Alzheimer’s disease drug trontinemab showed it might be able to clear brain plaques faster than other medicines.

Drugs 278

Drugs Medicine 278

Bio Pharma Dive

MARCH 11, 2024

Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

Drugs 270

Drugs Protein Medicine Development 270

Bio Pharma Dive

FEBRUARY 22, 2024

The startup’s Series C round will support a clinical-stage drug the company thinks could address some of the weaknesses of other KRAS-targeting medicines.

Drugs 297

Drugs Medicine 297

Pharmaceutical Technology

MAY 23, 2023

The US Food and Drug Administration (FDA) has granted approval for Blueprint Medicines’ Ayvakit (avapritinib) as the first and only treatment for indolent systemic mastocytosis (ISM) in adult patients.

FDA Approval 246

FDA Approval Medicine Trials Drugs 246

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 8, 2024

The Drugs Technical Advisory Board (DTAB) has suggested to the ministry of health and family welfare (MoHFW) to write to the ministry of corporate affairs to mandate the pharma companies to spend almost one per cent of their net profit for providing free medicines in medicine banks as part of the Corporate Social Responsibility (CSR). […]

Medicine 135

Medicine Pharma Companies Drugs Clinical Trials 135

Bio Pharma Dive

APRIL 25, 2023

Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.

FDA Approval 348

FDA Approval Medicine Protein Marketing 348

Bio Pharma Dive

MAY 6, 2024

The ability to modify drug formulations in real time and dosage strengths is crucial, while adhering to all regulatory standards and maintaining cGMP standards.

Pharmacy 138

Pharmacy Medicine Drugs 138

Drug Patent Watch

DECEMBER 26, 2023

Annual Drug Patent Expirations for AYVAKIT Ayvakit is a drug marketed by Blueprint Medicines and is included in one NDA. There are three patents… The post New patent for Blueprint Medicines drug AYVAKIT appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Medicine 59

Medicine Drugs Marketing 59

Pharmaceutical Technology

APRIL 26, 2024

In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.

Medicine 130

Medicine Development Drugs Marketing 130

Bio Pharma Dive

APRIL 12, 2024

The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.

Regulation 168

Regulation Drugs Medicine 168

Bio Pharma Dive

MAY 2, 2024

The funding will help Reunion pay for a mid-stage study testing its most advanced medicine — essentially a synthetic version of the hallucinogenic psilocin — in women with postpartum depression.

Medicine 290

Medicine Drugs 290

Pharmaceutical Technology

OCTOBER 18, 2023

Lisata has received orphan drug designation from the EMA's Committee for Orphan Medicinal Products for LSTA1 to treat pancreatic cancer.

Drugs 286

Drugs Medicine Production 286

Pharmaceutical Technology

JANUARY 8, 2024

The US FDA has granted authorisation for Florida's drug importation programme under section 804 of the FD&C Act.

Medicine 246

Medicine Drugs 246

Bio Pharma Dive

APRIL 8, 2024

But many development hurdles still stand in the way of new medicines for the brain. Recent biotech company acquisitions have put emerging schizophrenia treatments in focus.

Medicine 337

Medicine Drugs Development 337

pharmaphorum

FEBRUARY 27, 2024

Next-generation technology is enabling drug discovery at an entirely new scale, accelerating the process, transforming therapies and advancing precision medicine, and resulting in better patient outcomes. In this podcast, Dr Mohit Jain, founder and CEO of Sapient, discusses personalised disease prediction, diagnostics, and therapies.

Medicine 116

Medicine Drugs 116

Bio Pharma Dive

SEPTEMBER 29, 2023

Shares in the biotech surged on Phase 1 trial results for an oral GLP-1 drug Structure is developing, reflecting investor enthusiasm for the weight loss medicines.

Drugs 270

Drugs Medicine Trials Development 270

Bio Pharma Dive

AUGUST 29, 2023

The list includes the top-selling blood thinners Eliquis and Xarelto, as well as the arthritis drug Enbrel and heart failure medicine Entresto.

Drugs 285

Drugs Medicine 285

Fierce Pharma

FEBRUARY 22, 2024

As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. | As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new U.S. owner in Rigel Pharmaceuticals.

Medicine 106

Medicine Drugs 106

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 21, 2022

The Union Ministry of Ayush’s ‘One Herb, One Standard’ policy mandates evaluation of drug standards and quality control in medicinal plants.

Medicine 133

Medicine Drugs Clinical Trials Clinical Trials 133

Bio Pharma Dive

MAY 1, 2024

The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma and COPD.

Regulation 256

Regulation Drugs Medicine 256

Bio Pharma Dive

MAY 2, 2024

Delphia is developing medicines designed to overstress certain cellular pathways to the point tumor cells die, an approach the biotech calls “activation lethality.”

Medicine 289

Medicine Drugs Development 289

Pharmaceutical Technology

MARCH 1, 2024

Panama’s government expects to be a pioneer in the area through the centralisation of drug procurement with an emphasis on pharmacovigilance.

Medicine 147

Medicine Drugs Marketing 147

Bio Pharma Dive

AUGUST 1, 2023

The all-stock deal is a quiet end for the ambitious biotech, which was sold for its billion-dollar bank account after the FDA derailed its plans to develop low-cost cancer medicines.

Medicine 130

Medicine Drugs Development 130

Bio Pharma Dive

MARCH 21, 2024

Though the medicine hit its goal in a Phase 3 study in myasthenia gravis, the results fell short of expectations in a boost to rival drug developers like Argenx and AstraZeneca.

Drugs 168

Drugs Trials Medicine Development 168

Bio Pharma Dive

APRIL 1, 2024

The drug, inaxaplin, is an important pipeline prospect for Vertex, which is working to expand beyond the cystic fibrosis medicines that made its name.

Drugs 154

Drugs Medicine 154

Bio Pharma Dive

MARCH 7, 2023

Rapport Therapeutics aims to find new so-called receptor-associated proteins that could serve as targets for neurological disease medicines. Its most advanced drug is already in early-stage human testing.

Drugs 362

Drugs Protein Medicine 362

Bio Pharma Dive

MAY 30, 2023

The biotech said a committee advising the European Medicines Agency is “trending” toward issuing a negative opinion of its drug Relyvrio, which was approved in the U.S. last year.

Drugs 290

Drugs Medicine 290

Bio Pharma Dive

APRIL 22, 2024

The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

Manufacturing 270

Manufacturing Medicine Drugs 270

Bio Pharma Dive

MARCH 20, 2024

The biotech, which raised $540 million in an initial public offering last year, is pitching the medicine as a potential challenger to Amgen’s blockbuster eye drug Tepezza.

Drugs 168

Drugs Trials Medicine 168

Bio Pharma Dive

DECEMBER 8, 2022

As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.

Drugs 321

Drugs Antibody Medicine Development 321

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 7, 2024

A drug used to treat diabetes slowed the progression of motor issues associated with Parkinson’s disease, a study published in the New England Journal of Medicine said Wednesday. Parkinson’s is a devastating nervous system disorder affecting 10 million people worldwide, with no current cure.

Drugs 180

Drugs Medicine Clinical Trials Clinical Trials 180

Pharmaceutical Technology

NOVEMBER 1, 2022

Intrinsic Medicine has signed a definitive business combination agreement with special purpose acquisition (SPAC) firm Phoenix Biotech Acquisition to create a public company. To be named Intrinsic Medicine following closing, the combined company will be led by current Intrinsic CEO Alexander Martinez and president and COO Jason Ferrone.

Medicine 147

Medicine Clinical Trials Clinical Trials Drugs 147

Bio Pharma Dive

AUGUST 22, 2023

The pharma’s suit, which claims Medicare’s new power to negotiate certain drug prices is unconstitutional, comes days before the agency will reveal the first 10 medicines to be included under the plan.

Drugs 243

Drugs Medicine 243

Bio Pharma Dive

NOVEMBER 29, 2022

At a medical conference, the companies detailed clinical trial results that could help support approval of their drug, lecanemab. However, some doctors aren’t yet convinced the medicine’s risks are worth its potential benefits.

Doctors 358

Doctors Doctor Drugs Clinical Trials 358

Bio Pharma Dive

AUGUST 28, 2023

GPCRs, a ubiquitous family of proteins that are prime drug targets, have drawn the interest of companies like Structure Therapeutics, Septerna and now Superluminal Medicines.

Drugs 246

Drugs Protein Medicine 246